Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Q1 FY23 Earnings Presentation
25 slides from Jb Chemicals & Pharmaceuticals's earnings presentation, Aug 4, 2022
Slide 1: Investor Presentation cover letter to NSE
— GOOD PEOPLE _for GOOD HEALTH August 4, 2022 National Stock Exchange of India Limited Exchange Plaza, 5‘ Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai — 400051. Stock Symbol: JBCHEPHARM Dear Sir, Subject: Investor Presentation Enclosed please find the presentation the Compa
Slide 2: JB Pharma - Q1 FY23 Financial Results
JB Pharma - Q1 FY23 Financial Results August 4, 2022 www.jbpharma.com jbpharma/ 1
Slide 3: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 4: Corporate Overview
Corporate Overview 3
Slide 5: Corporate Snapshot
Corporate Snapshot Years of operations with Brands among top 300 brands, 46 consistent track record across multiple businesses 5 contributing over 60% of domestic formulations revenues Global manufacturer of Regulated/semi-regulated 40+ markets of presence through direct operations and distributors
Slide 6: Corporate Snapshot – Financial Overview
Corporate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) *Op EBITDA Margin (%) 42% 27.4% 25.0% 29% 21.3% 24% 22% 18.6% 15.4% 15% 25% 2,424 2,043 19% 18% 1,643 1,775 1,413 13% 10% 449 386 139 194 272 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 ROE (%) ROCE (%) Increasing Share of t
Slide 7: World Class Manufacturing Facilities
World Class Manufacturing Facilities Seven state-of-the-art manufacturing facilities in Western India Over 40 global regulatory accreditations US FDA EU – GMP HEALTH – Canada SAHPRA – South Africa MHRA – UK TGA – Australia MOH – Russia Producing a wide array of dosage forms 6
Slide 8: Q1 FY23 Business Performance
Q1 FY23 Business Performance 7
Slide 9: CEO’s Message
CEO’s Message “Our operating performance in FY23 started on a strong note. We continued the momentum in our domestic business, registering market beating growth and achieving a new milestone in quarterly run-rate revenue of over INR 400 crore. Integration of Sanzyme's product range and Azmarda have
Slide 10: Financial Overview Q1 FY23 vs Q1 FY22
Financial Overview Q1 FY23 vs Q1 FY22 Revenues (INR cr) o JB recorded robust revenue growth at 30% despite a 30% 785 challenging operating environment 606 • Organic revenue growth was around 20% o Domestic Formulations business continued its strong performance growing at 34% to INR 418 cr • Organic
Slide 11: EBITDA Analysis
EBITDA Analysis INR crore Q1 FY23 Q1 FY22 FY22 Revenue 785 606 2424 Reported EBITDA 173 164 543 Non Cash ESOP Cost 17 - 62 Included in Employee Benefits expense Operating EBITDA (excluding ESOP Cost) 190 164 605 Operating EBITDA Margin 24.2% 27% 25% 10
Slide 12: Financial Overview Q1 FY23 vs Q1 FY22
Financial Overview Q1 FY23 vs Q1 FY22 o Operating EBITDA* grew by 16% to INR 190 crores Op. EBITDA* (INR cr) o Gross margins were at 62.7% v/s 64.2% 190 (**24.2%) • Excluding Azmarda, gross margins for the business were relatively 16% flat YoY • Overall material cost continues to remain challenging
Slide 13: Domestic Business Q1 FY23 vs Q1 FY22
Domestic Business Q1 FY23 vs Q1 FY22 o Domestic Business records highest ever sales in a quarter of INR 418 crore registering growth of 34% Domestic Formulations (INR cr) o Organic revenue from the domestic business grew around mid-teens 418 out-pacing industry growth rate 34% o JB continues to rema
Slide 14: JB continues to be the fastest growing company in IPM
JB continues to be the fastest growing company in IPM, maintaining market beating performance Leadership position Market beating growth in the covered markets Fastest growing company among the Top 25 in the IPM 24% Vs IPM growth of 8% 35% + share in 7 molecule categories Outperformed the CVM growing
Slide 15: Prescription wise JB now Ranks #15
Prescription wise JB now Ranks #15 #15 Prescription Ranking • JB now ranks #15 in IPM as per IQVIA 57% prescription data gaining one rank (IQVIA 409 MAT June’22 vs MAT June’21) 261 • JB’s prescription base increased from 2.61 12% cr prescriptions in Q1 FY22 to 4.09 cr in Q1 FY23, growing at 57% 73.3
Slide 16: International Business Q1 FY23 vs Q1 FY22
International Business Q1 FY23 vs Q1 FY22 International Business (INR cr) 366 28% o International business recorded robust revenue growth of 28% to 287 INR 366 crores • Exports formulations, CMO and API business recorded growth of 11%, 108% and 17% respectively o South Africa unit registered growth
Slide 17: Financial Performance (Consolidated)
Financial Performance (Consolidated) Particulars Q1 FY23 Q1 FY22 YoY Growth FY22 FY21 Growth Revenue from Operations 785 606 30% 2424 2043 19% Cost of Goods Sold 293 217 35% 843 701 20% Gross Profit 492 389 26% 1581 1341 18% Gross Profit Margins 62.7% 64.3% 65.2% 65.7% Employee Benefit Expenses 134
Slide 18: Further Expanding Our Product Range - Acquisition of the Paediatric Portfolio
Further Expanding Our Product Range -Acquisition of the Paediatric Portfolio 17
Slide 19: Acquisition of Paediatric Brands: Leveraging on Existing Capabilities
Acquisition of Paediatric Brands: Leveraging on Existing Capabilities Market FY22 Business Overview Key Brands Market Share* sales* Triclofos JB acquired 4 Paediatric brands from Dr Hypnotic agent used in Reddy’s Pedicloryl Paediatric MS 76% 9 Crs Insomnia/Idiopathic Pain Internal sales of INR 3
Slide 20: Paediatric segment expected to reach 18,000 Crs by 2025
Paediatric segment continues to be a promising segment driving IPM growth, expected to reach 18,000 Crs by 2025 After a significant Covid impact, Paedia market has …propelling sales that is expected to grow at bounced back strongly, with a 10% Rx growth… 12% reaching 18,000 Crs in the next 3 years P
Slide 21: JB Strengthening its Presence Across all major Paediatric Therapeutic Areas
JB Strengthening its Presence Across all major Paediatric Therapeutic Areas Covering all major Paediatric therapeutic areas Idiopatic Pain/ Anti-infectives Gastro and Gut Skin & Wound Anti-parasitic Pro-biotics Insomnia Rantac Pecef/ Duo Metrogyl P/ DG Gutpro Laxolite Metrogyl range Pedi
Slide 22: Paediatric portfolio acquisition benefits
JBs paediatric portfolio will enjoy better market reach & will be part of a dedicated paedia division ACQUISITION BENEFITS Comprehensive Portfolio with well known brands to cater to paediatricians Increased market coverage and will align with our Go To Market model Productivity Leverage as existing
Slide 23: JB Pharma – Looking ahead – FY 2023
JB Pharma – Looking ahead –FY 2023 Domestic business to consistently outperform market growth driven by: Big brands becoming bigger Market share and prescription gains in acquired portfolio of probiotics, heart-failure & paediatric segment Life cycle management and new launches Continued growt
Slide 24: About JB Pharma
About JB Pharma J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | For further information, please ISIN: INE572A01028), established in 1976, is one of contact: the fastest growing pharmaceutical companies in India and a leading player in the hypertension Lakshay Kataria, Chief Financial Officer segment. B
Slide 25: Thank you
Thank you www.jbpharma.com 24
J.B. Chemicals & Pharmaceuticals — Q1 FY23 Earnings Presentation on 6ix